Summit Corporation's Pye on positive data for DMD treatment

Summit Corporation (LON:SUMM), a UK-based drug discovery and development company, has just reported some positive results from stage 1 trials of its new treatment for Duchenne Muscular Dystrophy. Director Dr Richard Pye tells Proactive Investors that although this is not a cure, it could help prevent muscle deterioration in this 'orphan' medical condition and prolong the life expectancy of young patients.